Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
24 Aprile 2024 - 10:05AM
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer, today announced that an abstract presenting
preliminary data from the phase 2 combination study of AFM24, its
innate cell engager (ICE®), in combination with atezolizumab,
Roche’s checkpoint inhibitor, in patients with EGFR-wildtype
(EGFRwt) non-small cell lung cancer (NSCLC) has been accepted for
poster presentation at 2024 American Society of Clinical Oncology
(ASCO) Annual Meeting.
Details of the poster presentation are as
follows:
Title: Preliminary results from
the phase 2 study of AFM24 in combination with atezolizumab in
patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer
(NSCLC)
Presenting Author: Hye Ryun
Kim
Poster Session: Developmental
Therapeutics—Immunotherapy
Abstract Number: 2522
Poster Presentation Time:
Saturday, June 1, 2024, 9:00 a.m. - 12:00 p.m. CDT
The full abstract will become available on
ASCO’s website on May 23, 2024 at 5:00 p.m. (EDT). More details
about the ASCO conference are available online at Attend | ASCO
Annual Meeting.
About AFM24 AFM24 is a
tetravalent, bispecific ICE® that activates the innate immune
system by binding to CD16A on innate immune cells and epidermal
growth factor receptors (EGFR), a protein widely expressed on solid
tumors, to kill cancer cells. Generated by Affimed’s
fit-for-purpose ROCK® platform, AFM24 represents a distinctive
mechanism of action that uses EGFR as a docking site to engage
innate immune cells for tumor cell killing through
antibody-dependent cellular cytotoxicity and antibody-dependent
cellular phagocytosis.
About Affimed N.V. Affimed
(Nasdaq: AFMD) is a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer by actualizing the untapped potential of the innate immune
system. The Company’s innate cell engagers (ICE®) enable a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors. ICE® are generated on the Company’s
proprietary ROCK® platform which predictably generates customized
molecules that leverage the power of innate immune cells to destroy
tumor cells. A number of ICE® molecules are in clinical
development, being studied as mono- or combination therapy.
Headquartered in Mannheim, Germany, Affimed is led by an
experienced team of biotechnology and pharmaceutical leaders united
by the bold vision to stop cancer from ever derailing patients’
lives. For more about the Company’s people, pipeline and partners,
please visit: www.affimed.com.
Forward-Looking Statement
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements appear in a number of
places throughout this release and include statements regarding the
Company’s intentions, beliefs, projections, outlook, analyses and
current expectations concerning, among other things, the potential
of acimtamig (AFM13), AFM24, AFM28 and the Company’s other product
candidates, the value of its ROCK® platform, its ongoing and
planned preclinical development and clinical trials, its corporate
restructuring, the associated headcount reduction and the impact
this may have on Company’s anticipated savings and total costs and
expenses, its collaborations and development of its products in
combination with other therapies, the timing of and its ability to
make regulatory filings and obtain and maintain regulatory
approvals for its product candidates, its intellectual property
position, its collaboration activities, its ability to develop
commercial functions, clinical trial data, its results of
operations, cash needs, financial condition, liquidity, prospects,
future transactions, growth and strategies, the industry in which
it operates, the macroeconomic trends that may affect the industry
or the Company, such as the instability in the banking sector
experienced in the first quarter of 2023, impacts of the COVID-19
pandemic, the benefits to Affimed of orphan drug designation, the
impact on its business by political events, war, terrorism,
business interruptions and other geopolitical events and
uncertainties, such as the Russia-Ukraine conflict, the fact that
the current clinical data of acimtamig in combination with NK cell
therapy is based on acimtamig precomplexed with fresh allogeneic
cord blood-derived NK cells from The University of Texas MD
Anderson Cancer Center, as opposed to Artiva’s AlloNK® NK cells and
other uncertainties and factors described under the heading “Risk
Factors” in Affimed’s filings with the SEC. Given these risks,
uncertainties, and other factors, you should not place undue
reliance on these forward-looking statements, and the Company
assumes no obligation to update these forward-looking statements,
even if new information becomes available in the future.
Investor Relations Contact
Alexander FudukidisDirector, Investor
RelationsE-Mail: a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin Vice President, Marketing and
CommunicationsE-Mail: m.sandin@affimed.com
Grafico Azioni Affimed NV (NASDAQ:AFMD)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Affimed NV (NASDAQ:AFMD)
Storico
Da Mag 2023 a Mag 2024